Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors

NCT05247905 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT05247905
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05247905 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Randomized, Prospective Trial of Lutetium Lu 177 Dotatate PRRT Versus Capecitabine and Temozolomide in Well-Differentiated Pancreatic Neuroendocrine Tumors
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 16, 2023
Completion date
October 1, 2033
Enrollment
31 (actual)
Sites
171

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic neuroendocrine tumor, unresectable pancreatic neuroendocrine carcinoma